This budget impact analysis of nirmatrelvir/ritonavir (NMV/r) for treating mild-to-moderate COVID-19 at high-risk of severe…
This cost-effectiveness analysis of nirmatrelvir/ritonavir (NMV/r) vs. best supportive care for treating mild-to-moderate COVID-19 in…
The U.S. Inflation Reduction Act enabled CMS to negotiate Medicare drug prices. In this commentary,…
This meta-analysis of 224 studies on colorectal cancer (CRC) reveals a 4.1% HER2 positivity (HER2+)…
Curta was selected to bring our decades of experience in HEOR to an initiative of…
In this worked example using Curta’s Oncology Simulation Model (OSM) framework, Curta researchers examined the…
Seeking HEOR researchers to join our team!
Curta partners Sean Sullivan, Josh Carlson, and David Veenstra and colleagues released a joint statement…
Using a mathematical model and clinical trial data, Curta investigators estimated for the year 2031…
Curta is seeking two talented individuals to join our team, specifically in roles of data…
2022 – What an incredible year we’ve had!
October’s edition of Frontiers in Oncology features an article co-authored by two Curta researchers, Ashley…
